Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats

• Published in: Journal of inorganic biochemistry 2014-02, Vol.131, p.115-122
• Main Authors: Domingues, N., Pelletier, J., Ostenson, C.-G., Castro, M.M.C.A.
• Format: Article
• Language: English
• Subjects: Adipocytes - drug effects; Adipose Tissue - drug effects; Adipose Tissue - metabolism; Animals; Blood Glucose - metabolism; Body Weight - drug effects; Cells, Cultured; Coordination Complexes - pharmacology; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Glucose - metabolism; Glucose tolerance; Glucose Tolerance Test; Glucose uptake by adipocytes; Goto-Kakizaki rats; Hypoglycemic Agents - pharmacology; Insulin - pharmacology; Insulin Receptor Substrate Proteins - metabolism; Insulin signaling pathway; Male; Medicin och hälsovetenskap; Molecular Mimicry; Organometallic Compounds - pharmacology; Protein Tyrosine Phosphatase, Non-Receptor Type 1 - metabolism; Proto-Oncogene Proteins c-akt - metabolism; Rats; Rats, Wistar; Type 2 diabetes; VO(dmpp)2
• ISSN: 0162-0134; 1873-3344; 1873-3344
• DOI: 10.1016/j.jinorgbio.2013.11.005

The bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), VO(dmpp)2, has shown anti-diabetic effects by in vitro studies in Wistar (W) rat adipocytes and in vivo in obese Zucker rats. The aim of this work is to confirm the therapeutic properties of VO(dmpp)2 in non-obese type 2 diabetic Goto-Kakizaki (GK) rats. An in vivo study was carried out, treating W and GK rats during 21days with a daily dose of VO(dmpp)2 (44μmol/kg). It was shown that VO(dmpp)2 doesn't affect the normal increase of body weight of both W and GK rats, after 8days of treatment ameliorates glycemia in GK rats (8.4±0.3 vs 10.1±0.2mM in GK control, P